We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Experts Debate Early Trial Stoppage for J&J’s Supplemental Zytiga Apps
Experts Debate Early Trial Stoppage for J&J’s Supplemental Zytiga Apps
June 20, 2012
Experts are wondering whether Johnson & Johnson (J&J) made the right decision when it unblinded its pivotal trial for a supplemental indication for prostate cancer treatment Zytiga before the study met its overall survival endpoint.